The Australian Government has taken a historic step by approving federal funding for psychedelic-assisted psychotherapy (PAP) for veterans suffering from post-traumatic stress disorder (PTSD) and treatment-resistant depression (TRD). Through the Department of Veterans’ Affairs (DVA), eligible veterans will now be able to access MDMA or psilocybin treatments within a regulated clinical setting at no personal cost.

PAREA unites pan-European patient organizations, medical associations, scientific societies, and psychedelic foundations to promote evidence-based policymaking and prepare health systems for the adoption of psychedelic therapies. 

PAREA is a supporting partner of the Psychedelic Lived Experiences Summit, taking place November 21–23. This free, online event focuses on the realities of psychedelic care by placing lived experience at the center of the conversation.

The European Investment Bank (EIB) and European Investment Fund (EIF) have secured commitments from a group of leading institutional investors to create the Scaleup Europe Fund, a €5 billion initiative to help high-growth European companies stay and grow within the EU.

Psilocybin Therapy for Psychological Distress in Palliative Care Patients (PsyPal) - the first EU-funded clinical trial of psychedelic therapy - is now underway and actively recruiting participants across its four trial sites in Copenhagen, Groningen, Lisbon and Prague. 

On October 31 and November 1, PAREA participated in the IMBAS Psychedelic Research Conference at Trinity College Dublin, the second edition of Ireland's leading event on psychedelic science. 

In October, PAREA participated in LaPsyConf 2025, the first international conference in Buenos Aires dedicated to rethinking mental health, longevity, and emerging therapeutics. Tadeusz Hawrot, Founder of PAREA, delivered the opening address titled “Global Issues: Mental Health Indicators, Global Regulation, and Economic Impact.”

Spain’s Council of Ministers has formally approved a Royal Decree establishing the country’s first regulatory framework for the medical use of cannabis in standardised preparations. The decision aims to provide an alternative therapeutic option when conventional treatments fail.

The Global Burden of Disease (GBD) 2023 update, published in The Lancet, shows that mental health conditions are rising faster than almost any other group of disorders worldwide. Drawing on data from more than 200 countries, the study remains the most comprehensive analysis of global health loss and life expectancy.